Episode 45: ESMO 2026 Commentary: Bladder Cancer
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
Recorded in Madrid at ESMO 2026, Dr. Aly-Khan Lalani and Dr. Christopher Wallis kick off a three-part series highlighting the latest advances in GU cancer care, beginning with bladder cancer.
With perioperative treatment for muscle-invasive bladder cancer evolving rapidly, Dr. Lalani and Dr. Wallis revisit the NIAGARA trial alongside emerging findings from ENERGIZE and KEYNOTE-866, comparing key trial outcomes and exploring their potential implications for clinical practice.
The conversation also explores emerging ctDNA biomarker data from KEYNOTE-B15/EV-304, new findings from KEYNOTE-905/EV-303, and the highly anticipated VOLGA trial. Dr. Lalani and Dr. Wallis examine the evolving roles of antibody-drug conjugates and immunotherapy, weighing treatment efficacy against potential toxicity, and highlighting the questions that remain around optimizing perioperative care.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.